Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

X-radiation remains the treatment of choice in most cases of leukemia and lymphoma, but new agents are playing an increasing role in therapy. Radioactive phosphorus does not produce radiation sickness and results with it are comparable to those of x-ray therapy in chronic leukemia. Urethane and nitrogen mustard may produce remissions in patients with chronic leukemia who have become resistant to radiation. Triethylene melamine may be administered orally with nitrogen mustard-like effects and is undergoing further trial. Aminopterin, ACTH and cortisone often cause short remissions in acute leukemia. Urethane is the best treatment available for multiple myeloma. Polycythemia vera is well controlled by radioactive phosphorus combined with venesection. Nitrogen mustard is often effective and triethylene melamine shows promise in Hodgkin's disease. Antianemic substances such as iron and liver extract are of no value in the treatment of anemia caused by leukemia, lymphoma and myeloma.
 ...
PMID:New therapy for leukemia, polycythemia, and lymphoma. 1301 1

Spontaneous reticulum cell neoplasms developed in 70-80% of intact male and female SJL/J mice at a mean age of 380 days. The neoplasms had a basic histological pattern of a multicellular type-B reticulum cell neoplasm, as designated by Dunn. The tumors were transplanted in isogenic mice. Serial passages of cell suspensions of these tumors were carried on through at least 4 tumor-inducing generations, and the growing transplanted tumors maintained the structure of a reticulum cell neoplasm similar to the original tumor. A histological survey of spontaneous lesions in SJL/J mice revealed different characteristics of reticulum cell neoplasms, some similar to Hodgkin's lesions. Five or ten feedings of 7,12-dimethylbenz-[alpha]anthracene (DMBA) in polyethylene glycol 400 (1 mg DMBA per feeding) to SJL/J mice induced lymphosarcomas in 74-83% of the mice at a mean age of 157-188 days. A single feeding of DMBA induced lymphosarcomas in only 27% of the mice at a mean age of 246 days. These DMBA-induced lymphatic leukemias do not appear to depend on the thymus for development--a 60% incidence of lymphosarcomas was obtained in adult thymectomized mice treated with DMBA, and 27% of the thymectomized DMBA-treated mice developed myeloid leukemia at a mean age of 180 days. Urethan was only slightly leukemogenic in SJL/J mice.
 ...
PMID:Studies on leukemia development in the SJL/J strain of mice. 1862 27